Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
Funding the next wave of data center growth.
stocks
Chart of the Week: BHP’s growth story faces a reality check
China’s slowing economy could weigh on BHP’s future growth.
stocks
3 best ASX growth stocks to buy for the long term
Here’s three high-quality growth companies with wide moats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.80 | 41.20 | -0.46% |
| CAC 40 | 8,377.86 | 4.57 | -0.05% |
| DAX 40 | 24,915.49 | 84.04 | -0.34% |
| Dow JONES (US) | 52,552.97 | 105.67 | -0.20% |
| FTSE 100 | 10,572.24 | 56.32 | 0.54% |
| HKSE | 24,650.45 | 358.15 | -1.43% |
| NASDAQ | 25,881.95 | 387.28 | -1.47% |
| Nikkei 225 | 63,896.48 | 2,939.06 | -4.40% |
| NZX 50 Index | 13,638.57 | 23.79 | 0.17% |
| S&P 500 | 7,533.77 | 38.63 | -0.51% |
| S&P/ASX 200 | 8,785.10 | 31.70 | -0.36% |
| SSE Composite Index | 3,834.73 | 47.68 | -1.23% |